ADIPOQ and cancer: Accordingly, clinically low plasma adiponectin levels are associated with increased cancer risk [25–27] and adiponectin is considered to be antitumorigenic from studies that showed it reduced tumorigenic activity in breast [28–31], endometrial [32–34], colorectal [35–37], prostate [38–41], and pancreatic cancers [25].